NanoGroup SA (NNG) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN Million ()

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.79

Return on Equity

-60.85%

Price to Book

0.00

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.86%

6 Months

-0.19%

1 Year

7.5%

2 Years

172.15%

3 Years

109.76%

4 Years

-44.99%

5 Years

-47.35%

NanoGroup SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-8.30%

EBIT Growth (5y)

-193.06%

EBIT to Interest (avg)

-5.58

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.60

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

0.36

EV to EBITDA

0.36

EV to Capital Employed

-0.26

EV to Sales

-2.19

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-66.71%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -38.46% vs 27.78% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.00",
          "val2": "-1.30",
          "chgp": "-53.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-1.30",
          "chgp": "-38.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-647,500.00%",
          "chgp": "64,750.00%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 34.18% vs -887.50% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.10",
          "val2": "-16.60",
          "chgp": "69.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-7.90",
          "chgp": "34.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,465,642.90%",
          "val2": "-8,238,281.80%",
          "chgp": "5,77,263.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.00

-1.30

-53.85%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.80

-1.30

-38.46%

Operating Profit Margin (Excl OI)

0.00%

-647,500.00%

64,750.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -38.46% vs 27.78% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.10

-16.60

69.28%

Interest

0.00

Exceptional Items

-0.00

0.00

Consolidate Net Profit

-5.20

-7.90

34.18%

Operating Profit Margin (Excl OI)

-2,465,642.90%

-8,238,281.80%

5,77,263.89%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 34.18% vs -887.50% in Dec 2023

All Annual Results

Company CV

About NanoGroup SA

NanoGroup SA

Pharmaceuticals & Biotechnology

Nanogroup SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.

Company Coordinates

Company Details

Ul. Rakowiecka 36 , WARSZAWA None : 02-532

Tel:

http://nanogroup.eu/

Registrar Details